Elias Obeid, MD, MPH, discusses the phase 3 KATHERINE trial in HER2-positive breast cancer.
Elias Obeid, MD, MPH
Advertisement
Articles by Elias Obeid, MD, MPH
Elias Obeid, MD, MPH, assistant professor, Department of Clinical Genetics, Fox Chase Cancer Center, discusses a retrospective analysis that investigated androgen receptor expression in patients with triple-negative breast cancer. (TNBC).
Advertisement
Latest Updated Articles
Dr. Elias Obeid on Androgen Receptor Expression in Triple-Negative Breast CancerPublished: March 8th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5